Back to Search
DAVID BRADLEY, D.O.
D.O.
Physical Medicine & Rehabilitation Physician
NPI: 1639294259IndividualAccepts Medicare
Specialties, Licenses & Credentials
Physical Medicine & Rehabilitation PhysicianPrimary
Physical Medicine & Rehabilitation
Code: 208100000X
52167(MN)PT14574(ND)14574(ND)
CMS Specialties
PrimaryPAIN MANAGEMENT
Education
LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE, ERIE
Class of 2002
Clinical Trials (2)
2
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Alterations in energy balance following exenatide administration.
PMID 22735035·Appl Physiol Nutr Metab·2012
3-trial
Prediabetes: the importance of early identification and intervention.
PMID 20675976·Postgrad Med·2010
6-review
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.
PMID 20876408·Arch Intern Med·2010
4-observational
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
PMID 20413733·Arterioscler Thromb Vasc Biol·2010
3-trial
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.
PMID 18332269·Circulation·2008
8-other
Relationship between beta-cell mass and diabetes onset.
PMID 18834430·Diabetes Obes Metab·2008
7-preclinical
Weight loss therapy improves pancreatic endocrine function in obese older adults.
PMID 18388888·Obesity (Silver Spring)·2008
2-rct
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
PMID 17468345·Diabetes Care·2007
2-rct
Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
PMID 16755277·Pharmacogenomics J·2007
8-other
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
PMID 15111485·Diabetes·2004
3-trial
Accurate assessment of beta-cell function: the hyperbolic correction.
PMID 11815482·Diabetes·2002
6-review
Temporal discrimination threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia.
PMID 19525326·Brain·2009
8-other
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
PMID 18814988·Magn Reson Imaging·2009
7-preclinical
Pathogens promote plant diversity through a compensatory response.
PMID 18312409·Ecol Lett·2008
8-other
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
PMID 17458919·NMR Biomed·2008
7-preclinical
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.
PMID 17534443·Neoplasia·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- ESSENTIA HEALTH SOUTH UNIVERSITY CLINIC, 1702 UNIVERSITY DRIVE SOUTH
FARGO, ND 58103 - Phone
- (701) 364-3300
Quick Facts
- NPI
- 1639294259
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 24
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile